What is the USPSTF recommendation for HIV preexposure prophylaxis?

What is the USPSTF recommendation for HIV preexposure prophylaxis?

• A. Clinicians should prescribe PrEP to all adults.
• B. Clinicians should prescribe PrEP to persons at increased risk of HIV acquisition.
• C. Clinicians should not prescribe PrEP due to cost.
• D. Clinicians should prescribe PrEP only after a negative HIV test.

Answer: (B)

The key point is that HIV PrEP is recommended for people who are at increased risk of acquiring HIV, not for everyone. The USPSTF endorses offering PrEP to those with substantial risk, based on strong evidence that it reduces new HIV infections when used by the right individuals. In practice, this means clinicians assess each patient’s risk factors and provide PrEP to those at higher risk, with initial HIV testing to confirm they’re negative and ongoing HIV testing and monitoring while on PrEP. Prescribing PrEP to all adults would misapply the targeted prevention approach, since not everyone has elevated risk. The notion that PrEP should be avoided because of cost isn’t consistent with the guidance, which supports PrEP for those at high risk while acknowledging cost and access considerations in real-world implementation. The idea of prescribing only after a negative HIV test captures part of the process (necessary baseline testing) but oversimplifies initiation and ongoing monitoring, which also include risk assessment and periodic testing during use.

The key point is that HIV PrEP is recommended for people who are at increased risk of acquiring HIV, not for everyone. The USPSTF endorses offering PrEP to those with substantial risk, based on strong evidence that it reduces new HIV infections when used by the right individuals. In practice, this means clinicians assess each patient’s risk factors and provide PrEP to those at higher risk, with initial HIV testing to confirm they’re negative and ongoing HIV testing and monitoring while on PrEP.

Prescribing PrEP to all adults would misapply the targeted prevention approach, since not everyone has elevated risk. The notion that PrEP should be avoided because of cost isn’t consistent with the guidance, which supports PrEP for those at high risk while acknowledging cost and access considerations in real-world implementation. The idea of prescribing only after a negative HIV test captures part of the process (necessary baseline testing) but oversimplifies initiation and ongoing monitoring, which also include risk assessment and periodic testing during use.